<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8606714</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4754</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Child Neurol.</journal-id>
<journal-title-group>
<journal-title>Journal of child neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29246093</article-id>
<article-id pub-id-type="pmc">5739082</article-id>
<article-id pub-id-type="doi">10.1177/0883073817696814</article-id>
<article-id pub-id-type="manuscript">NIHMS851704</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jeong</surname>
<given-names>Anna</given-names>
</name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wong</surname>
<given-names>Michael</given-names>
</name>
<degrees>MD, PhD</degrees>
</contrib>
<aff id="A1">Department of Neurology and the Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO</aff>
</contrib-group>
<author-notes>
<corresp id="FN1">Corresponding author: Michael Wong, MD, PhD, Department of Neurology, Box 8111, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110; Phone: 314-362-8713; Fax: 314-362-9462. wong <email>m@wustl.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Declaration of Conflicting Interests</bold>
</p>
<p>The authors have no conflict of interest to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>33</volume>
<issue>1</issue>
<fpage>55</fpage>
<lpage>63</lpage>
<!--elocation-id from pubmed: 10.1177/0883073817696814-->
<abstract>
<p id="P1">Malformations of cortical development represent a common cause of epileptic encephalopathies and drug-resistant epilepsy in children. As current treatments are often ineffective, new therapeutic targets are needed for epileptic encephalopathies associated with cortical malformations. The mechanistic/mammalian target of rapamycin (mTOR) pathway constitutes a signaling pathway that drives cellular and molecular mechanisms of epileptogenesis in a variety of focal cortical malformations. mTOR inhibitors prevent epilepsy and associated pathogenic mechanisms of epileptogenesis in mouse models of tuberous sclerosis complex and are currently in clinical trials for drug-resistant seizures in these patients. A recent explosion of genetic studies has linked mutations in various genes regulating the mTOR pathway to other cortical malformations, such as focal cortical dysplasia and hemimegalencephaly. Thus, mTOR inhibitors represent promising candidates as novel antiseizure and antiepileptogenic therapies for epilepsy associated with a spectrum of cortical malformations.</p>
</abstract>
<kwd-group>
<kwd>epilepsy</kwd>
<kwd>epileptogenesis</kwd>
<kwd>everolimus</kwd>
<kwd>malformation of cortical development</kwd>
<kwd>mTOR</kwd>
<kwd>rapamycin</kwd>
<kwd>seizures</kwd>
<kwd>tuberous sclerosis</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>